Sherlock Biosciences competitors

Paula Brown Stafford is a biopharmaceutical services executive and leadership consultant with more than 30 years of industry experience. She is currently the President and Chief Operating Officer for Novan, Inc., as well as a Managing Director for Habergeon LLC. Ms. Stafford retired in 2015 from her position as President of Clinical Development at Quintiles (now part of iQvia). Ms. Stafford’s global responsibilities encompassed Phase I-IV clinical research services and she served as a member of Quintiles Executive Committee. She was an Independent Director for BioImaging, later BioClinica (NASDAQ: BIOC), from 2002 to 2008. In addition, Ms. Stafford served as a member of the CDISC (Clinical Data Interchange Standards Consortium) Board of Directors for 9 years, serving as Chair for 2 years and as a member of the Executive Committee for 6 years. Ms. Stafford is an Adjunct Professor in Public Health Leadership for the UNC-CH Gillings School of Global Public Health and emeritus member of the UNC-CH Public Health Foundation Board. In 2011, Ms. Stafford received the Triangle Business Journal’s Women in Business Award. FierceBiotech named Ms. Stafford one of the 10 top women in biotech in 2012. Ms. Stafford holds a Bachelor of Science and a Master of Public Health in Biostatistics from the University of North Carolina at Chapel Hill. In 2016, the university honored Ms. Stafford with its Distinguished Alumna Award.

Chris Cappello is a President/CEO at Pharmajet and Board Member at Pharmajet. He has worked as Chief Operating Officer at Pharmajet. Chris studied at Colorado State University.

Jigar Raythatha joined Jounce Therapeutics in December 2012 after a 15 year career in the biotechnology industry in a variety business functions. Most recently, Jigar Raythatha was the head of corporate development of Constellation Pharmaceuticals, Inc. where he was instrumental in securing over $175 million in non-dilutive and equity funding. In addition, Jigar Raythatha negotiated and subsequently led the company's broad epigenetics strategic alliance with Genentech and established Constellation's project management and market development capabilities. Prior to Constellation, Jigar Raythatha worked with Red Abbey Venture Partners, initially as a Kauffman fellow, later as a principal, and finally a venture partner. During his tenure at Red Abbey, Jigar Raythatha led or participated in all of the firm's investments, including Advanced BioHealing (acquired by Shire), Aegerion Pharmaceuticals (IPO), Cogenesys (acquired by Teva), and Stromedix (acquired by Biogen Idec). Previously, Jigar Raythatha has worked with Biogen, Inc. and Pfizer, Inc. in business development and new product planning roles. Jigar Raythatha holds an M.B.A. from Columbia Business School and a B.A. in molecular biology and biochemistry and economics from Rutgers University.